Impact of Stem Cell-Based Therapy and Platelet-Rich Plasma in Hair Loss and Telogen Effluvium Related to COVID-19

    July 2023 in “ Regenerative Therapy
    Pietro Gentile, Simone Garcovich
    New to Platelet-Rich Plasma? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This systematic review found an increased incidence of hair loss and telogen effluvium among COVID-19 patients and reported preliminary effectiveness of platelet-rich plasma, adipose-derived mesenchymal stem cells, and human follicle stem cells for treatment without major side effects.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The systematic review analyzed 12 studies to evaluate the increased incidence of hair loss (HL) and telogen effluvium (TE) in COVID-19 patients, and the effectiveness of Platelet-Rich Plasma (PRP), Adipose-derived Mesenchymal Stem Cells (AD-MSCs), and Human Follicle Stem Cells (HFSCs) in these patients. The data confirmed an increased incidence of HL and TE in COVID-19 patients and the preliminary effectiveness of AD-MSCs, HFSCs, and PRP without major side effects. 84% of the studies showed a clear correlation between HL, TE, and COVID-19, and 68% of the studies showed a positive impact of regenerative strategies, including PRP and stem cell-based therapies, against HL related to COVID-19. However, the review highlighted the need for further research to define standardized protocols and large-scale trials to confirm the effectiveness of these regenerative therapies.
    Discuss this study in the Community →

    Research cited in this study

    28 / 28 results